Projects overview

Sort by

Toggle all information

COMBACTE-CDI | Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

01-11-2017

-

30-04-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-01 ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)

LITMUS | Liver Investigation: Testing Marker Utility in Steatohepatitis

01-11-2017

-

29-02-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-05 IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ACROSS THE SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

EQIPD | European Quality In Preclinical Data

01-10-2017

-

30-09-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-03 DATA QUALITY IN PRECLINICAL RESEARCH AND DEVELOPMENT

RTCure | Rheuma Tolerance for Cure

01-09-2017

-

31-08-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-02 DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES
Powered by Chris Decubber BV